VistaGen Therapeutics (NASDAQ:VTGN) Given "Sell (D-)" Rating at Weiss Ratings

Key Points

• VistaGen Therapeutics has been assigned a "Sell (D-)" rating by Weiss Ratings, amidst a mixed consensus from analysts with ratings ranging from "Buy" to "Sell".
• The stock price of VistaGen Therapeutics saw a 1.5% increase, reaching $4.02 during trading, with a market capitalization of $123.33 million.
• Institutional investors hold a significant majority, owning approximately 78.39% of the company's stock, with several hedge funds increasing their stakes recently.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

VTGN has been the topic of a number of other research reports. Wall Street Zen upgraded shares of VistaGen Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. William Blair reiterated an "outperform" rating on shares of VistaGen Therapeutics in a research note on Wednesday, June 18th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold".

VistaGen Therapeutics Stock Up 1.5%

Shares of VTGN stock traded up $0.06 during mid-day trading on Wednesday, reaching $4.02. 533,962 shares of the company's stock traded hands, compared to its average volume of 300,295. VistaGen Therapeutics has a 12 month low of $1.90 and a 12 month high of $4.25. The company has a market cap of $123.33 million, a P/E ratio of -2.26 and a beta of 0.55. The company's 50-day moving average price is $3.26 and its 200-day moving average price is $2.66.

VistaGen Therapeutics (NASDAQ:VTGN - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, meeting analysts' consensus estimates of ($0.47). The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.22 million. Equities analysts predict that VistaGen Therapeutics will post -1.77 earnings per share for the current year.

Hedge Funds Weigh In On VistaGen Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ADAR1 Capital Management LLC lifted its stake in VistaGen Therapeutics by 246.4% during the 1st quarter. ADAR1 Capital Management LLC now owns 420,765 shares of the company's stock valued at $1,052,000 after acquiring an additional 299,304 shares during the period. Millennium Management LLC increased its position in shares of VistaGen Therapeutics by 52.9% during the 4th quarter. Millennium Management LLC now owns 38,732 shares of the company's stock valued at $114,000 after purchasing an additional 13,395 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of VistaGen Therapeutics during the 2nd quarter valued at about $190,000. Marshall Wace LLP purchased a new stake in shares of VistaGen Therapeutics during the 2nd quarter valued at about $69,000. Finally, Bank of America Corp DE increased its position in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company's stock valued at $62,000 after purchasing an additional 19,331 shares during the last quarter. Institutional investors own 78.39% of the company's stock.

About VistaGen Therapeutics

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.